drugset / Trial / NCT02393794
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Phase 1/2
Active not recruiting
51 enrolled
Priyanka Sharma
Bristol-Myers Squibb · collabCelgene Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study combination use of cisplatin plus romidepsin and nivolumab in metastatic triple negative breast cancer (TNBC) or BRCA mutation-associated locally recurrent or metastatic breast cancer
Timeline
- Start
- 2015-07-17
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 360 mg | — |
| Subject | Romidepsin | Peptide | 8 mg/m2 | Intravenous |
| Subject | Romidepsin | Peptide | 10 mg/m2 | Intravenous |
| Subject | Romidepsin | Peptide | 12 mg/m2 | Intravenous |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |